妥布霉素雾化吸入联合静脉使用抗生素治疗呼吸机相关性肺炎有效性和安全性观察

Efficacy and safety of tobramycin aerosol inhalation combined with intravenous antibiotics in the treatment of VAP

目的:探究妥布霉素雾化吸入联合静脉抗生素治疗呼吸机相关性肺炎(VAP)患者的临床疗效和安全性。方法:2018年6月-2019年8月收治VAP患者82例,随机分为两组,各41例。对照组给予敏感抗生素静脉给药治疗;观察组在抗生素基础上给予妥布霉素雾化吸入给药治疗。比较两组治疗总有效率和不良反应发生率。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:妥布霉素雾化吸入联合抗生素静脉给药治疗VAP效果显著,具有较高的用药安全性。

Objective:To explore the efficacy and safety of tobramycin aerosol inhalation combined with intravenous antibiotics in the treatment of patients with VAP.Methods:From June 2018 to August 2019,82 VAP patients were selected and randomly divided into two groups with 41 cases in each group.The control group was treated with sensitive antibiotics intravenously.The observation group was treated with tobramycin aerosol inhalation on the basis of antibiotics.We compared the total effective rate and the incidence of adverse reactions between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of tobramycin aerosol inhalation combined with intravenous antibiotics in the treatment of patients with VAP is significant,and it has a high drug safety.